Clinical trials: Normal Healthy
Acne Vulgaris
Study to Investigate the Irritation Potential of GSK1940029 Gel
The proposed indication for GSK1940029 is topical treatment of acne, the early clinical plan will evaluate the irritation potential of GSK1940029 (Study SCD117225 - 3 Part study); and safety, tolerability and pharmacokinetics of…
- Trial name
- NCT01984801
- Testing
- 0.3% GSK1940029 gel, 1% GSK1940029 gel, 0.3%/1% vehicle gel only
- Where
- Australia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy, Renal Impairment
Comparative Study of Quinine Sulfate in Healthy Patients and in Patients With Renal Impairment
The effects of mild or moderate renal impairment (creatinine clearance 30 to 50 ml/min or >50 to 80 ml/min, respectively) on the pharmacokinetic profile of quinine and its active metabolite, 3'-hydroxyquinine, will be…
- Trial name
- NCT00785551
- Testing
- quinine sulfate
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Food Effect in Healthy Volunteers
A Study to Assess the Effect of Food on the Absorption and Bioavailability of PBI-200
This is a single-dose, open-label, randomized, three-way crossover study to assess the effect of food on the absorption and bioavailability of PBI-200.
- Trial name
- NCT05160389
- Testing
- PBI-200
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pyramid Biosciences
Psoriasis
Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008
The purpose of this study is to determine how the organism affects MMF (metabolite of dimethyl fumarate [DMF]) after single oral dose administration of LAS41008 120 mg gastroresistant tablet and Fumaderm® 120 mg gastro-resistant…
- Trial name
- LAS41008 (NCT02955693)
- Testing
- LAS41008 120 mg / Fumaderm® 120 mg
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Almirall, S.A.
Health Adult Subjects, Atopic Dermatitis (AD)
Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
This is a Phase I/II, multicenter, randomized, double-blind, placebo-controlled study evaluating HXN6005 in healthy participants and patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT07782476
- Testing
- HXN6005
- Where
- China
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
Renal Impairment
Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function
Renal excretion is a minor elimination route of telotristat etiprate. So this trial is intended to assess the drug behaviour in subjects with decreased renal function.
- Trial name
- NCT03442725
- Testing
- Telotristat etiprate
- Where
- 4 sites in Belgium, Germany and 2 more
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Ipsen
Atopic Dermatitis
Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis
This is the first time PF-07242813 will be given to humans. The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07242813 in healthy participants and…
- Trial name
- NCT04668066
- Testing
- PF-07242813
- Where
- 7 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Pfizer
Rheumatoid Arthritis
Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects
This is a randomized, double-blind, placebo-controlled, single-dose, dose escalation study in healthy male and or female subjects and subjects with Rheumatoid Arthritis (RA) to determine the safety and tolerability of MORAb-022.
- Trial name
- NCT01357759
- Testing
- MORAb-022
- Where
- 5 sites in United States, Netherlands
- Volunteers
- 20 people
- Sponsor
- Morphotek
Psoriasis
Trial of HSK44459 Cream for the Management Plaque Psoriasis
Phase I Study Objectives: Primary: Assess the safety and tolerability of HSK44459 cream in 10 healthy adult participants and 10 patients with plaque psoriasis.
- Trial name
- NCT07623486
- Testing
- HSK44459 Cream, Vehicle
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Healthy Volunteers
Assessment of Pharmacokinetics (PK) and Safety of M834 and Orencia ®, in Healthy Subjects
The purpose of this study is assess the pharmacokinetics and safety of M834 and Orencia ® following administration of a single-dose in healthy volunteers.
- Trial name
- NCT02923583
- Testing
- M834, US-Sourced Orencia®, EU-Sourced Orencia®
- Where
- 2 sites in United Kingdom
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- Momenta Pharmaceuticals, Inc.
Healthy Volunteers
Bioequivalence Study of Cyclosporine 100mg Capsule Under Fed Condition
To demonstrate bioequivalence between Test Product (A):Cyclosporine Soft Gelatin Capsules Modified 100 mg manufactured by Panacea Biotec Ltd, India and the corresponding Reference Product (B):Neoral (Cyclosporine…
- Trial name
- NCT01080586
- Testing
- Cyclosporine Capsules USP (Modified) 100 mg
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Panacea Biotec Ltd
Rheumatoid Arthritis
Proximod Pharmacokinetics In Healthy Subjects
The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Proximod in healthy subjects. The main questions it arms to answer are: 1.
- Trial name
- NCT06361186
- Testing
- Proximod
- Where
- China
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Longevity Inc.
Healthy Subjects, Cold Urticaria
A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria
This is a first-in-human study aimed at determining the safety of a single dose of GTX-B001 in healthy participants and in people with chronic inducible urticaria.
- Conditions
- Healthy Subjects, Cold Urticaria, Symptomatic Dermographism, Chronic Inducible Urticaria
- Trial name
- CHILL-MC (NCT07181369)
- Testing
- GTX-B001, Normal Saline
- Where
- 5 sites in Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Granular Therapeutics Limited
Fabry Disease
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
This study will assess the safety, tolerability, and pharmacokinetics (PK) study of a single dose of 150 mg AT1001 (migalastat HCl, GR181413A) administered orally to healthy subjects with normal renal function and to subjects…
- Trial name
- NCT01730469
- Testing
- AT1001 150 mg
- Where
- 4 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amicus Therapeutics
Neoplasms, Medication Toxicity
Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers
This is a Phase 1 study, which will assess the safety, PK, and pharmacodynamics (PD) of orally-administered AMXT 1501 dicaprate in normal healthy male volunteers.
- Conditions
- Neoplasms, Medication Toxicity, Tolerance
- Trial name
- NCT03077477
- Testing
- AMXT 1501
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Aminex Therapeutics, Inc.
Fasting
Minocycline HCl Extended Release Tablets 135 mg Oral Bioequivalence Study
To determine single-dose oral bioequivalence of Minocycline HCl Extended Release Tablets 135 mg manufactured by Amneal Pharmaceuticals Co.(I)Pvt.
- Trial name
- Minocycline (NCT01067001)
- Where
- India
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Amneal Pharmaceuticals Co. India Private Limited
Anthrax
Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects
Valortim is the name of the experimental drug that volunteers will receive in this study. Valortim may also be called MDX-1303. Experimental means that the drug is not yet approved by the Food and Drug Administration (FDA).
- Trial name
- NCT01265745
- Testing
- Normal Saline for Injection, MDX1303
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- PharmAthene, Inc.
Hepatic Impairment
INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
This is a phase I, multi-center, open-label, single oral dose, parallel group study to evaluate the pharmacokinetics and safety of INC280 in non-cancer subjects with impaired hepatic function and non-cancer subjects with normal…
- Trial name
- NCT02474537
- Testing
- INC280
- Where
- 5 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants
This is a Phase 1, first-in-human (FIH), randomized, double-blind, single-dose, parallel-group, 3-arm study to compare PK, safety, tolerability, and immunogenicity profiles of CKD-704, EU-approved Skyrizi, and US-licensed Skyrizi…
- Trial name
- NCT07258745
- Testing
- SKYRIZI, CKD-704
- Where
- Poland
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Staphylococcus (S.) Aureus Infection
A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.
In this study, the candidate vaccine LTB-SA7 will be tested for safety and immunogenicity in healthy adults.
- Trial name
- LTBSA701 (NCT06719219)
- Testing
- LTB-SA7
- Where
- United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- LimmaTech Biologics AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.